Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort

Recently, autoimmune encephalitis (AE) has been widely studied in the field of neurological autoimmune diseases [1]. The number of known AE subtypes is constantly increasing owing to advances in testing methods. To date, >10 novel antibodies against extracellular proteins, including antibodies against leucine-rich glioma-inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2), and contactin-2, have been identified. These antibodies are now classified as voltage-gated potassium channel-complex (VGKC) antibodies, which have similar clinical significance and are considered to be directly pathogenic [2,3].